Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

OCUL is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of OCUL shares has increased $0.15 since the market last closed. This is a 1.71 ...

OCUL is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of OCUL shares has increased $0.03 since the market last closed. This is a 0.34 ...

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable ...

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.